----item----
version: 1
id: {18D37A7F-C67E-48FA-876A-599B466D8EAA}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/03/16/Coronado nabs preclinical cancer assets from NeuPharma
parent: {15CEDA49-DF2B-4F46-96A7-78145A6DFE0C}
name: Coronado nabs preclinical cancer assets from NeuPharma
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 30a67cf7-01a1-436a-9e48-c1fc2f6cb781

----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 54

Coronado nabs preclinical cancer assets from NeuPharma
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 54

Coronado nabs preclinical cancer assets from NeuPharma
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1253

<p>After a restructuring of the company a little more than a year ago, Coronado Biosciences is continuing to add to its pipeline portfolio &ndash; the biotech struck a deal with NeuPharma on 19 March for an undisclosed number of preclinical cancer assets. Coronado agreed to pay an undisclosed up front fee, as well as development- and sales-based milestones. Coronado also agreed to single-digit sales royalties on any products that result. The biotech will develop and commercialize irreversible, third-generation epidermal growth factor receptor (EGRF) inhibitors worldwide, except for Asian countries. The deal comes about a year after Coronado's lead therapy &ndash; a treatment for Crohn's disease developed using parasitic worms &ndash; failed in Phase II trials to show any effectiveness beyond a placebo (<a href="http://#http://www.scripintelligence.com/home/Coronados-worm-therapy-fails-in-Crohns-trial-stock-drops-67-347306" target="_new">scripintelligence.com, 14 October 2013</a>). The clinical trial failure forced Coronado to pare down the company (<a href="http://#http://www.scripintelligence.com/home/BioNotebook-Ariad-Merrimack-Tetraphase-Incyte-Coronado-347951" target="_new">scripintelligence.com, 08 November 2013</a>). </p><p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 984

<p>After a restructuring of the company a little more than a year ago, Coronado Biosciences is continuing to add to its pipeline portfolio &ndash; the biotech struck a deal with NeuPharma on 19 March for an undisclosed number of preclinical cancer assets. Coronado agreed to pay an undisclosed up front fee, as well as development- and sales-based milestones. Coronado also agreed to single-digit sales royalties on any products that result. The biotech will develop and commercialize irreversible, third-generation epidermal growth factor receptor (EGRF) inhibitors worldwide, except for Asian countries. The deal comes about a year after Coronado's lead therapy &ndash; a treatment for Crohn's disease developed using parasitic worms &ndash; failed in Phase II trials to show any effectiveness beyond a placebo (<a>scripintelligence.com, 14 October 2013</a>). The clinical trial failure forced Coronado to pare down the company (<a>scripintelligence.com, 08 November 2013</a>). </p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 54

Coronado nabs preclinical cancer assets from NeuPharma
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150316T120001
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150316T120001
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150316T120001
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC028174
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 54

Coronado nabs preclinical cancer assets from NeuPharma
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{2D771726-4AE8-4124-B380-232612225CB7}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 4

News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

357305
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042314Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

30a67cf7-01a1-436a-9e48-c1fc2f6cb781
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042314Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
